Dual receptor agonist · randomised human trials
What is Tirzepatide?
Tirzepatide is a peptide medicine that acts as an agonist at GIP and GLP-1 receptors. These hormone pathways help regulate metabolism. Its dual-receptor mechanism distinguishes it from a GLP-1-only medicine such as semaglutide.
How does Tirzepatide work?
Receptor activation affects glucose-regulating and appetite-related processes. The response depends on the person, treatment context and formulation. It should not be interpreted as guaranteed fat loss or as a reason to copy someone else’s treatment. [1]
What does the research show?
The SURMOUNT-1 trial, published in 2022, enrolled 2,539 adults with obesity or overweight and a weight-related complication, excluding diabetes. It compared tirzepatide with placebo over 72 weeks and found greater average weight reduction in the treatment groups. [1]
What the evidence does not establish
Participants received a defined trial product and follow-up. The findings do not establish outcomes for every person, all medical conditions, or an unrelated compounded preparation. Gastrointestinal adverse effects were part of the trial’s safety findings.
Safety questions to discuss
Assessment should consider the full product information, medical history and other medicines. The trial is not a dosing guide for personal use. [2]
Frequently asked questions
What is the difference between tirzepatide and semaglutide?
Tirzepatide targets GIP and GLP-1 receptors; semaglutide targets GLP-1 receptors.
Are study averages a prediction for one person?
No. Trial averages describe groups and do not guarantee an individual result.
Sources and further reading
- SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity, 2022
- SAHPRA: peptide products public information
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.